Coya Therapeutics (COYA) EBT Margin (2023 - 2026)
Coya Therapeutics (COYA) posted EBT Margin of 2869.63% for Q1 2026, down 1226.31% sequentially from 216.36% in Q4 2025, and down 3628.0% YoY from 81.34% in Q1 2025.
Coya Therapeutics (COYA) EBT Margin (2023 - 2026) Analysis & Trends
Coya Therapeutics has reported EBT Margin for 4 years, with the latest figure at 2869.63% in Q1 2026.
- Quarterly EBT Margin fell 3628.0% year-over-year to 2869.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 336.71% (up 49833.0% YoY) and the FY2025 annual result came in at 266.81%, up 17213.0% from the prior year.
- EBT Margin fell to 2869.63% in Q1 2026 per COYA's latest filing, from 216.36% in the prior quarter.
- Over five years, EBT Margin peaked at 63.48% in Q4 2023 and troughed at 625479.97% in Q4 2024.
- A 4-year average of 71043.53% and a median of 2833.35% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin plunged 62541649 bps in 2024, then jumped 62526361 bps in 2025.
- Over 4 years, EBT Margin stood at 63.48% in 2023, then plunged by 985280 bps to 625479.97% in 2024, then jumped by 100 bps to 216.36% in 2025, then tumbled by 1226 bps to 2869.63% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 2869.63%, 216.36%, and 136.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -2,723.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,723.44% |
| Mar 31, 2026 | -2,869.63% |
| Dec 31, 2025 | -216.36% |
| Sep 30, 2025 | -136.40% |
| Jun 30, 2025 | -3,725.17% |
| Mar 31, 2025 | -2,833.35% |
| Dec 31, 2024 | -625,479.97% |
| Jun 30, 2024 | -84.42% |
| Mar 31, 2024 | -3,982.96% |
| Dec 31, 2023 | -63.48% |